GREENLAND MINES LTD Increase (Decrease) in Other Accounts Payable and Accrued Liabilities
GREENLAND MINES LTD (GRML) reported Increase (Decrease) in Other Accounts Payable and Accrued Liabilities of -$23.80 thousand for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-17.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities · last filed 2023-11-17
- GREENLAND MINES LTD increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2023-09-30 was $33.00K, a 16.03% decline year-over-year.
- GREENLAND MINES LTD increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2023-06-30 was $33.90K.
- GREENLAND MINES LTD increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2023-03-31 was -$90.70K.
- GREENLAND MINES LTD increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2022-12-31 was $44.20K.
- GREENLAND MINES LTD increase (decrease) in other accounts payable and accrued liabilities for fiscal 2022 was $122.80K.
| Period end | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2023-09-30 | $33.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-17 | $66.90K derived: sum of 2 quarters · filed 2023-11-17 | -$23.80K 10-Q · filed 2023-11-17 | $20.40K derived: sum of 4 quarters · filed 2023-11-17 |
| 2023-06-30 | $33.90K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-21 | -$56.80K 10-Q · filed 2023-08-21 | -$12.60K derived: sum of 3 quarters · filed 2023-10-18 | $26.70K derived: sum of 4 quarters · filed 2023-11-17 |
| 2023-03-31 | -$90.70K 10-Q · filed 2023-05-24 | -$46.50K derived: sum of 2 quarters · filed 2023-10-18 | -$7.20K derived: sum of 3 quarters · filed 2023-11-17 | |
| 2022-12-31 | $44.20K derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-10-18 | $83.50K derived: sum of 2 quarters · filed 2023-11-17 | $122.80K 10-K/A · filed 2023-10-18 | |
| 2022-09-30 | $39.30K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-17 | $78.60K 10-Q · filed 2023-11-17 | ||
| 2022-06-30 | $39.30K 10-Q · filed 2023-08-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |